Refine your search
About Osivelotor
Osivelotor is an HbS polymerization inhibitor designed to bind directly to HbS, to potentially reduce polymerization and red blood cell sickling.
Osivelotor has the potential to increase hemoglobin levels and reduce rates of vaso-occlusive crises (VOCs) at a low dose.
Ongoing and future clinical trials will determine whether the investigational medication is safe and/or effective.
About the clinical trial test
This clinical trial includes up to a 4-week screening period, a 2-week pre-treatment period, a 16-week treatment period, and a 4-week follow-up period.
Eligible participants will be randomized 1:1 to receive the study medicine or placebo twice daily for 16 weeks. Participants will also be provided wearable digital devices to monitor physical activity, gait, blood pressure, and pulse rate at designated intervals.
Participants will be enrolled for up to 26 weeks and will need to attend at least 9 in-person visits and 11 telehealth visits. Visits will include physical and neurological exams, blood draws, ECGs, MRIs, and other assessments.
A look inside our facility
Our clinical research unit is a modern facility that provides study-related clinical care and monitoring of the participants in our clinical trials. The New Haven Clinical Research Unit has 57 inpatient beds as well as outpatient facilities. Many of the studies include overnight stays. Within the research unit location, you’ll have access to internet, a large relaxation and reading area, and a multimedia room for entertainment. There is also a terrace available for fresh air.
Participants receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.
We also have a fully renovated outpatient clinic for vaccine studies. Take a look inside and learn more about vaccine clinical trials at the New Haven PCRU.
